Recent research involving 11,883 people with RA suggests that higher BMI may be linked to a lower response to JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. This doesn’t mean these treatments won’t work, but BMI may be one factor doctors consider when evaluating treatment response.